BRIEF-Bellus Health says Kiacta did not meet primary efficacy endpoint in phase 3 study
June 20 (Reuters) - Bellus Health Inc
* Announces top-line phase 3 results of kiacta for treatment of aa amyloidosis
* In study, Kiacta did not meet primary efficacy endpoint in slowing renal function decline
* Kiacta was shown to be safe and well tolerated over treatment periods of greater than 4 years
* Further analysis of data is ongoing. Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.